Analyses / MOH
Shares fell 6.6% on the day to $206.56 but remain about 70% up their 52-week range. Revenue growth is solid, while margins are thin and EPS is declining.
A free account reveals MOH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.
The Thesis
▲ Bull Case
Revenue grew 12.4% (5Y: 18.5%). Forward P/E 24.5x and P/S 0.25x. Insiders logged 47 purchase transactions versus 16 sales (147,484 shares bought vs 51,412 sold). Price remains well above the $121.06 52-week low. If the day's decline proves sentiment-driven, a recovery toward the $221 prior close is possible.
▼ Bear Case
Net margin is only 1.04% and operating margin 1.72%, so small cost shifts can move earnings. TTM EPS growth is -12.7%. Trailing P/E is unavailable. The stock fell 6.6% to $206.56 on a day with a $203.41 low, and the payload does not explain the cause. Policy headlines on Medicare and Medicaid billing are in the news flow.
Valuation
mixed — score 45/100
Forward P/E and EV/EBITDA are moderate, P/S is low, but thin margins and negative EPS growth limit the read. No sector benchmark in payload.
Technical Levels
Support · $203.41 (Day low) · $196.00 (Entry zone floor (derived)) · $121.06 (52-week low)
Resistance · $220.66 (Day high) · $221.21 (Prior close) · $244.89 (52-week high)
RSI: Not available in payload
Financial Health
Score 55/100. Liquidity ratios are adequate and beta is low. Leverage and coverage cannot be assessed from the payload.
Catalysts
| Next earnings report (date not in payload) | Not in payload | high |
| Medicare/Medicaid billing and marketplace enrollment policy | Ongoing (per Benzinga headline) | medium |
| Cause of the -6.6% day move (unconfirmed) | Recent session | medium |
Risk Flags
See MOH's full trade plan — free
Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.
Unlock MOH free →Recent News
- Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and MolinaYahoo
- 5 HMO Stocks to Watch Amid Sound Membership Base, Tech InnovationYahoo
- What Sent Molina Stock Higher?Yahoo
- Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace EnrollmentsBenzinga
- Does Molina Healthcare Stock's Run Make Any Sense?Yahoo
You've read your 2 free analyses
Create a free account for unlimited analyses — every name on the page, plus live tools on 5,000+ tickers. No card required.
Read the full MOH analysis — free →Free to read · 2 analyses every 30 days without an account
More Analyses
MOH FAQ
Is MOH a buy right now?
Molina Healthcare Inc's current read is a Post-drop reassessment setup with medium confidence over a 1-3 months horizon. Valuation: mixed. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.
Is MOH overvalued?
mixed (valuation score 45/100). Forward P/E and EV/EBITDA are moderate, P/S is low, but thin margins and negative EPS growth limit the read. No sector benchmark in payload.
What are the risks of buying MOH?
Net margin is only 1.04% and operating margin 1.72%, so small cost shifts can move earnings. TTM EPS growth is -12.7%. Trailing P/E is unavailable. The stock fell 6.6% to $206.56 on a day with a $203.41 low, and the payload does not explain the cause. Policy headlines on Medicare and Medicaid billing are in the news flow.